RhumbLine Advisers
NGNE icon

RhumbLine Advisers’s Neurogene NGNE Stock Holding History

RhumbLine Advisers’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$445K Buy
14,153
+261
+2% +$7.18K ﹤0.01% 2846
2026
Q1 		$280K Buy
13,892
+509
+4% +$9.86K ﹤0.01% 2943
2025
Q4 		$276K Sell
13,383
-1,676
-11% -$41.7K ﹤0.01% 3020
2025
Q3 		$261K Sell
15,059
-266
-2% -$5.34K ﹤0.01% 3085
2025
Q2 		$229K Sell
15,325
-368
-2% -$5.78K ﹤0.01% 3152
2025
Q1 		$184K Sell
15,693
-11
-0.1% -$191 ﹤0.01% 3143
2024
Q4 		$359K Buy
15,704
+1,326
+9% +$49.3K ﹤0.01% 2880
2024
Q3 		$603K Buy
14,378
+889
+7% +$34.5K ﹤0.01% 2577
2024
Q2 		$491K Buy
+13,489
New +$476K ﹤0.01% 2694
2022
Q2 		– Sell
-2,073
Closed -$78K – 3189
2022
Q1 		$78K Sell
2,073
-164
-7% -$9.57K ﹤0.01% 2934
2021
Q4 		$216K Sell
2,237
-30
-1% -$3.65K ﹤0.01% 2817
2021
Q3 		$328K Sell
2,267
-256
-10% -$39.2K ﹤0.01% 2735
2021
Q2 		$466K Buy
2,523
+763
+43% +$169K ﹤0.01% 2595
2021
Q1 		$433K Sell
1,760
-114
-6% -$29.1K ﹤0.01% 2557
2020
Q4 		$529K Buy
1,874
+172
+10% +$42K ﹤0.01% 2422
2020
Q3 		$409K Sell
1,702
-90
-5% -$21.8K ﹤0.01% 2380
2020
Q2 		$595K Buy
+1,792
New +$467K ﹤0.01% 2266

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

RhumbLine Advisers's NGNE Position: Q2 2026 in Review

RhumbLine Advisers increased its Neurogene (NGNE) stake by 1.9% in Q2 2026, buying an estimated $7.18K and bringing the position to 14,153 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #2846.

RhumbLine Advisers first reported a position in NGNE in Q2 2020 and has held it in 17 quarters since. The position peaked at $603K in Q3 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • RhumbLine Advisers held 14,153 shares of Neurogene worth $445K as of Q2 2026.
  • RhumbLine Advisers bought 261 Neurogene shares in Q2 2026, an estimated $7.18K.
  • Neurogene made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2846 holding.
  • RhumbLine Advisers first reported a position in Neurogene in Q2 2020 and has held it in 17 quarters since.
  • RhumbLine Advisers's Neurogene position peaked at $603K in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.